{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T20:23:08Z","timestamp":1783974188282,"version":"3.55.0"},"reference-count":55,"publisher":"Informa UK Limited","issue":"1","funder":[{"name":"Ministry of Science, Technological Development and Innovations of Republic of Serbia"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Drug Safety"],"published-print":{"date-parts":[[2024,1,2]]},"DOI":"10.1080\/14740338.2023.2293208","type":"journal-article","created":{"date-parts":[[2023,12,8]],"date-time":"2023-12-08T04:40:18Z","timestamp":1702010418000},"page":"67-78","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":1,"title":["Priapism associated with anti-seizure medications: a pharmacovigilance study and a review of published cases"],"prefix":"10.1080","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5592-5084","authenticated-orcid":false,"given":"Nemanja Z.","family":"Petrovi\u0107","sequence":"first","affiliation":[{"name":"Department of Pharmacology and Toxicology, Faculty of Medical Sciences, University of Kragujevac, Kragujevac, Serbia"},{"name":"Department of Clinical Pharmacology, University Clinical Center Kragujevac, Kragujevac, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1741-0025","authenticated-orcid":false,"given":"Ana V.","family":"Pej\u010di\u0107","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Toxicology, Faculty of Medical Sciences, University of Kragujevac, Kragujevac, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan R.","family":"Milovanovi\u0107","sequence":"additional","affiliation":[{"name":"Faculty of Medical Sciences, University of Kragujevac, Kragujevac, Serbia"},{"name":"Clinic of Urology, University Clinical Center Kragujevac, Kragujevac, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2023,12,11]]},"reference":[{"key":"e_1_3_5_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2013.11.008"},{"key":"e_1_3_5_4_1","volume-title":"StatPearls [internet]","author":"Silberman M","unstructured":"Silberman M, Stormont G, Leslie SW, et al. Priapism. In StatPearls [internet]. Treasure Island (FL): StatPearls Publishing; [cited 2023 Jul 11]. Available from. http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK459178\/"},{"key":"e_1_3_5_5_1","doi-asserted-by":"publisher","DOI":"10.1097\/JU.0000000000002767"},{"key":"e_1_3_5_6_1","doi-asserted-by":"publisher","DOI":"10.1212\/CON.0000000000001104"},{"key":"e_1_3_5_7_1","doi-asserted-by":"publisher","DOI":"10.1177\/03000605221133988"},{"key":"e_1_3_5_8_1","doi-asserted-by":"publisher","DOI":"10.14744\/epilepsi.2017.14632"},{"key":"e_1_3_5_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bjmsu.2009.04.001"},{"key":"e_1_3_5_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.1988.tb06391.x"},{"key":"e_1_3_5_11_1","doi-asserted-by":"publisher","DOI":"10.51271\/jpea-2021-0109"},{"issue":"12","key":"e_1_3_5_12_1","first-page":"4800","article-title":"Clozapine-induced priapism and subsequentvalproic acid-induced priapism a case of a 40-year old man with diagnosis of schizoaffective disorder with no previous history of priapism","volume":"5","author":"Shahpesandy H","year":"2019","unstructured":"Shahpesandy H, Mohammed-Ali R, Anene M, et al. Clozapine-induced priapism and subsequentvalproic acid-induced priapism a case of a 40-year old man with diagnosis of schizoaffective disorder with no previous history of priapism. Int J Curr Med Pharm Res. 2019;5(12):4800\u20134801.","journal-title":"Int J Curr Med Pharm Res"},{"key":"e_1_3_5_13_1","doi-asserted-by":"publisher","DOI":"10.4103\/0253-7613.121383"},{"key":"e_1_3_5_14_1","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.7721"},{"key":"e_1_3_5_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.genhosppsych.2015.06.010"},{"key":"e_1_3_5_16_1","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.21241"},{"key":"e_1_3_5_17_1","doi-asserted-by":"publisher","DOI":"10.4103\/0974-7796.141012"},{"key":"e_1_3_5_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajem.2019.11.027"},{"issue":"2","key":"e_1_3_5_19_1","first-page":"142","article-title":"A case of carbamazepine-induced priapism","volume":"28","author":"Gupta S","year":"2016","unstructured":"Gupta S, Sharma S, Buttar RS, et al. A case of carbamazepine-induced priapism. Ann Clin Psychiatry. 2016;28(2):142\u2013143.","journal-title":"Ann Clin Psychiatry"},{"key":"e_1_3_5_20_1","doi-asserted-by":"publisher","DOI":"10.1517\/14740338.2016.1112376"},{"key":"e_1_3_5_21_1","doi-asserted-by":"publisher","DOI":"10.2174\/1381612823666171004115230"},{"key":"e_1_3_5_22_1","doi-asserted-by":"publisher","DOI":"10.1177\/0018578718795271"},{"key":"e_1_3_5_23_1","unstructured":"US Food and Drug Administration. Questions and answers on FDA\u2019s adverse event reporting system (FAERS) [Internet]. FDA. 2018 [cited 2023 Jul 17]. Available from: http:\/\/www.fda.gov\/drugs\/surveillance\/questions-and-answers-fdas-adverse-event-reporting-system-faers"},{"key":"e_1_3_5_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2023.101967"},{"key":"e_1_3_5_25_1","doi-asserted-by":"publisher","DOI":"10.1177\/1460458219901232"},{"key":"e_1_3_5_26_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40780-017-0088-5"},{"key":"e_1_3_5_27_1","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.2113"},{"key":"e_1_3_5_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.14868"},{"key":"e_1_3_5_29_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0157753"},{"key":"e_1_3_5_30_1","unstructured":"WHO Collaborating Centre for Drug Statistics Methodology. WHOCC - ATC\/DDD Index: N03A Antiepileptics [Internet]. 2023 [cited 2023 Jul 8]. Available from: https:\/\/www.whocc.no\/atc_ddd_index\/?code=N03A&showdescription=no"},{"key":"e_1_3_5_31_1","unstructured":"KEGG BRITE database. Anatomical Therapeutic Chemical (ATC) Classification N03AG01 Valproic acid [DG:DG00849] [Internet]. 2023 [cited 2023 Jul 14]. Available from: https:\/\/www.genome.jp\/brite\/br08303+D00399"},{"key":"e_1_3_5_32_1","unstructured":"WHO Collaborating Centre for Drug Statistics Methodology. Guidelines for ATC classification and DDD assignment 2023. [Internet]. 2022. [cited 2023 Jul 14]. Available from: https:\/\/www.whocc.no\/filearchive\/publications\/2023_guidelines_web.pdf"},{"key":"e_1_3_5_33_1","unstructured":"World Health Organization. Executive summary from the 51st meeting of the WHO International Working group for drug Statistics Methodology Geneva 24-25 March 2022. [Internet]. 2022. [cited 2023 Jul 14]. Available from: https:\/\/cdn.who.int\/media\/docs\/default-source\/international-nonproprietary-names-(inn)\/atc-ddd\/51st_atc_ddd_executive_summary.pdf?sfvrsn=ef45dbc4_3&download=true"},{"key":"e_1_3_5_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.fct.2020.111767"},{"key":"e_1_3_5_35_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.677"},{"key":"e_1_3_5_36_1","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200730050-00001"},{"issue":"5","key":"e_1_3_5_37_1","first-page":"S141","article-title":"A rare case of priapism induced by sodium valproate in an adult with bipolar affective disorder","volume":"58","author":"Sahoo AJ","year":"2016","unstructured":"Sahoo AJ, Mohapatra S. A rare case of priapism induced by sodium valproate in an adult with bipolar affective disorder. Indian J Psychiatry. 2016;58(5):S141.","journal-title":"Indian J Psychiatry"},{"key":"e_1_3_5_38_1","doi-asserted-by":"publisher","DOI":"10.1177\/0092861512453041"},{"key":"e_1_3_5_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.euroneuro.2021.10.562"},{"key":"e_1_3_5_40_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M101287200"},{"key":"e_1_3_5_41_1","unstructured":"Sanofi. Depakote 250mg tablets - summary of product characteristics (SmPC) - (emc) [Internet]. 2022 [cited 2023 Jul 15]. Available from: https:\/\/www.medicines.org.uk\/emc\/product\/6102\/smpc"},{"key":"e_1_3_5_42_1","unstructured":"Sanofi. Epilim Chrono 200mg - summary of product characteristics (SmPC) - (emc) [Internet]. 2022 [cited 2023 Jul 15]. Available from: https:\/\/www.medicines.org.uk\/emc\/product\/3979\/smpc"},{"key":"e_1_3_5_43_1","doi-asserted-by":"publisher","DOI":"10.5455\/jmood.20120711044923"},{"key":"e_1_3_5_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-2999(99)00517-8"},{"key":"e_1_3_5_45_1","unstructured":"Novartis Pharmaceuticals UK Ltd. Tegretol 100mg tablets - summary of product characteristics (SmPC) - (emc) [Internet]. 2022 [cited 2023 Jul 15]. Available from: https:\/\/www.medicines.org.uk\/emc\/product\/1040\/smpc"},{"key":"e_1_3_5_46_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.chi.0000183496.44266.bd"},{"key":"e_1_3_5_47_1","doi-asserted-by":"publisher","DOI":"10.1080\/21548331.2017.1370969"},{"key":"e_1_3_5_48_1","unstructured":"Janssen-Cilag Ltd. Topamax 100mg tablets - summary of product characteristics (SmPC) - (emc) [Internet]. 2022 [cited 2023 Jul 15]. Available from: https:\/\/www.medicines.org.uk\/emc\/product\/1977\/smpc"},{"issue":"4","key":"e_1_3_5_49_1","first-page":"363","article-title":"Irreversible priapism during treatment with olanzapine and topiramate","volume":"19","author":"Schiraldi C","year":"2013","unstructured":"Schiraldi C, Todarello O. Irreversible priapism during treatment with olanzapine and topiramate. J Psychopathol. 2013;19(4):363\u2013364.","journal-title":"J Psychopathol"},{"key":"e_1_3_5_50_1","unstructured":"Rivopharm UK Ltd. Gabapentin 100 mg capsules - summary of product characteristics (SmPC) - (emc) [Internet]. 2019 [cited 2023 Jul 15]. Avail-able from: https:\/\/www.medicines.org.uk\/emc\/product\/2362\/smpc"},{"key":"e_1_3_5_51_1","unstructured":"Upjohn UK Limited. Lyrica 200 mg hard capsules - summary of product characteristics (SmPC) - (emc) [Internet]. 2023 [cited 2023 Jul 15]. Available from: https:\/\/www.medicines.org.uk\/emc\/product\/10307\/smpc"},{"key":"e_1_3_5_52_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ijir.3901165"},{"key":"e_1_3_5_53_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.psy.42.3.280-a"},{"key":"e_1_3_5_54_1","unstructured":"Aurobindo Pharma - Milpharm Ltd. Levetiracetam 1000 mg film-coated tablets - summary of product characteristics (SmPC) - (emc) [Internet]. 2022 [cited 2023 Jul 15]. Available from: https:\/\/www.medicines.org.uk\/emc\/product\/3072\/smpc"},{"key":"e_1_3_5_55_1","unstructured":"Aurobindo Pharma - Milpharm Ltd. Phenytoin 100mg film-coated tablets - summary of product characteristics (SmPC) - (emc) [Internet]. 2023 [cited 2023 Jul 15]. Available from: https:\/\/www.medicines.org.uk\/emc\/product\/4225\/smpc"},{"key":"e_1_3_5_56_1","unstructured":"GlaxoSmithkline UK Lamictal tablets - summary of product characteristics (SmPC) - (emc) [Internet]. 2023 [cited 2023 Jul 15]. Available from: https:\/\/www.medicines.org.uk\/emc\/product\/8052\/smpc"},{"key":"e_1_3_5_57_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.sxmr.2020.10.003"}],"container-title":["Expert Opinion on Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14740338.2023.2293208","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,24]],"date-time":"2024-09-24T17:39:06Z","timestamp":1727199546000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14740338.2023.2293208"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,11]]},"references-count":55,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1,2]]}},"alternative-id":["10.1080\/14740338.2023.2293208"],"URL":"https:\/\/doi.org\/10.1080\/14740338.2023.2293208","relation":{},"ISSN":["1474-0338","1744-764X"],"issn-type":[{"value":"1474-0338","type":"print"},{"value":"1744-764X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,11]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieds20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieds20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2023-08-24","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-11-28","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-12-11","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}